<DOC>
	<DOCNO>NCT00373516</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety two dose regimen QRX-101 ointment ( 75 mcg/g QD 75mcg/g BID ) treatment plaque-type psoriasis apply topically twice daily 8 week</brief_summary>
	<brief_title>Safety Efficacy Study Two Dose Regimens Becocalcidiol Treatment Plaque-Type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Clinical diagnosis stable plaquetype psoriasis affect 2 % 10 % subject â€™ body surface area Psoriasis severity appropriate treatment topical therapy ; PGA least 3 ( moderate ) baseline ; PSS least 7 , individual symptom score ( erythema , induration , scale ) less 2 Subject must sign IRB approve informed consent agree follow dose instruction complete require clinic visit . Pregnant nursing female Systemic corticosteroid , methotrexate , cyclosporine , systemic retinoids , prolong sun exposure ultraviolet light therapy within 4 week dose Topical corticosteroid , retinoids , calcipotriene , coal tar , anthralin , treatment indicate psoriasis within 2 week dose Untreated bacterial , tubercular , fungal viral lesion skin Biologic agents/monoclonal antibody last 6 month Currently use lithium plaquenil Currently use betablocking medication thiazide diuretic dose stabilize least 6 month History hypercalcemia evidence vitamin D toxicity Current history melanoma skin cancer past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>topical therapy</keyword>
</DOC>